Avalo Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
01/04/2024 18:57
* Avalo Therapeutics Inc AVTX.OQ reported a quarterly
adjusted
loss of $116.21 per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-249.60. The lone analyst forecast for the
quarter was for a loss of $4.80 per share.
* Revenue fell 36.3% to $571.00 thousand from a year ago;
analysts
expected $300.00 thousand.
* Avalo Therapeutics Inc's reported EPS for the quarter was
a loss
of $116.21.
* The company reported a quarterly loss of $8.17 million.
* Avalo Therapeutics Inc shares had held steady so far this
quarter and gained 139.0% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "hold"
This summary was machine generated from LSEG data April 1 at
05:57 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Dec. 31 2023 -4.80 -1.16 hundred Missed
Sep. 30 2023 -2.64 hundred -26.40 Beat
Jun. 30 2023 -1.92 hundred -1.42 hundred Beat
Mar. 31 2023 -2.33 hundred -2.04 hundred Beat